Comparison of the Cellular Content of Bone Marrow Aspiration From the Posterior Superior Iliac Spine and Deep Humeral Harvest in Patients Undergoing Rotator Cuff Repair

The goal of this observational clinical trial is to determine whether the posterior superior iliac spine of the hip or the humerus of the arm will produce larger amounts of bone marrow when harvested during surgery. Also, the secondary goal of this study is to determine the effects of the patient's position on the quantity of cells harvested from the hip, namely lying on back (prone) vs. lying on side (lateral decubitus). The main questions it aims to answer are:
* Will the hip or the arm have more bone marrow extracted?
* Does a patient lying in lateral decubitus position produce more bone marrow than lying in the prone position?
Participants that are to undergo rotator-cuff repair are eligible for this study. During the participant's repair, bone marrow will be extracted from the arm and from the hip. Half of the eligible participants will have bone marrow extracted from the hip while lying on their side, while the other half will have bone marrow extracted from the hip while lying on their back. Researchers will compare the results from both extraction sites on each patient, as well as compare results of the two patient position groups.

Start Date16 Aug 2022

Sponsor / Collaborator

Andrews Research & Education Foundation, Inc.

[+1]

NCT05582226

/ Unknown statusNot ApplicableIIT

A Randomized, Single Blinded Study of the Augmentation of Anterior Cruciate Ligament Reconstruction Using Stump-Derived Mesenchymal Stem Cells Versus Standard of Care Anterior Cruciate Ligament Reconstruction

The goal of this observational study is to compare patient outcomes for reconstructive surgery of ACL tears. This study utilizes two randomized groups, one being the control group that receives standard ACL reconstructive surgery, while the other is the test group at will receive an injection of stem cells taken from elsewhere within the body. The main objectives are to determine the usefulness of stem cells as a cost-effective implant in reconstructive surgery and to determine if the stem cells provide more optimized healing outcomes.
Participants will:
* Receive ACL reconstructive surgery as normal
* One-half of the participants will receive stem cells at the repair site as the test group
* All participants will have 3, 6, 9, 12, 18, and 24 month followups to chart their recovery progress Thus, the outcomes of the group receiving stem cell injections will be compared directly with the outcomes of the standard ACL reconstructive care group.

Start Date16 Aug 2022

Sponsor / Collaborator

Andrews Research & Education Foundation, Inc.

[+1]

NCT05735899

/ RecruitingNot ApplicableIIT

Evaluation of the Safety and Efficacy of Meniscal Preservation Surgery to Correct Meniscal Extrusion

The primary objective of this study is to demonstrate the safety and efficacy of surgical meniscal preservation techniques to correct meniscal extrusion. The primary endpoint for safety will be analysis of the total number and types of adverse events (AEs) and serious adverse events (SAEs). The primary endpoint for efficacy will include analysis of patient report outcome measures (PROMs).
H0 - Participants undergoing surgical meniscal preservation to correct meniscal extrusion will not exhibit a limited number of safety events nor have favorable outcomes.
H1- Participants undergoing surgical meniscal preservation to correct meniscal extrusion will exhibit a limited number of safety events and have favorable outcomes.

Start Date16 Aug 2022

Sponsor / Collaborator

Andrews Research & Education Foundation, Inc.

100 Clinical Results associated with Andrews Research & Education Foundation, Inc.

0 Patents (Medical) associated with Andrews Research & Education Foundation, Inc.

Literatures (Medical) associated with Andrews Research & Education Foundation, Inc.

01 Oct 2025·Pain and Therapy

Adherence to CONSORT-PRO Extension Guidelines for Patient-Reported Outcomes in Randomized Controlled Trials Focused on Peripheral Nerve Blocks: A Meta-epidemiological Study

Article

Author: Nguyen, Tiffany ; Dunford, Bryan ; Khan, Taimoor ; Vassar, Matt ; Shepard, Samuel ; Khan, Adam ; Khalid, Mahnoor ; Hartwell, Micah ; Stallings, Landon ; Terrell, Ashlyn ; Hillman, Cody ; Kee, Micah ; Ottwell, Ryan ; Roberts, Will

INTRODUCTION:

Patient-reported outcomes (PROs), such as peri- and postoperative pain scores, capture patient perspectives in regional anesthesia trials. However, whether these outcomes are reported according to established guidelines remains unclear. The CONSORT statement and its PRO extension (CONSORT-PRO) aim to enhance transparency in reporting PROs, yet no study has investigated adherence in peripheral nerve block (PNB) trials. Our meta-epidemiological investigation evaluated how well PNB randomized controlled trials (RCTs) adhere with CONSORT-PRO and explored whether trial characteristics affect reporting quality.

METHODS:

We performed a cross-sectional, meta-epidemiological study to determine adherence to CONSORT-PRO reporting guidelines in RCTs. We searched Cochrane Central Register of Controlled Trials (CENTRAL), Embase, and MEDLINE for RCT publications investigating PNBs between 2006 and 2020. RCTs investigating PNBs that incorporated PROs as a primary or secondary outcome were included. All other studies, reviews, or publications without a PRO were excluded.

RESULTS:

In total, 65 RCTs met the inclusion criteria. Mean CONSORT-PRO adherence was 46.80 ± 17.36%, and trials that designated a PRO as the primary endpoint were more adherent than those in which the PRO was secondary (49.27 ± 16.58% versus 38.57 ± 17.92%; P = 0.035). Trials with ≥ 6-month follow-up were 16.24% more adherent than those with ≤ 3-month follow-up (P = 0.006). Studies that used a visual analog scale (VAS) or numeric rating scale (NRS) in combination with other PRO instruments were significantly more adherent than trials using VAS alone (P = 0.028).

CONCLUSIONS:

Our meta-epidemiological review reveals substantial nonadherence to CONSORT-PRO guidelines in PNB trials. Although PROs are crucial for capturing patient-centered outcomes, they remain under-reported, especially when treated as secondary endpoints. Using diverse, validated measures beyond VAS/NRS and consistently applying CONSORT-PRO can enhance the quality, transparency, and clinical relevance of future trials. Targeted education for authors, editors, and clinicians-and expanded research on neuraxial techniques-will further strengthen reporting standards and the interpretability of anesthesia evidence.

01 Oct 2025·CLINICS IN SPORTS MEDICINE

Orthobiologic Use in Ligament Reconstruction and Repair

Review

Author: Waller, Garrett ; Truett, Jessi ; Anz, Adam

Ligament injuries are a common type of musculoskeletal condition, with an estimated 17 million occurring annually in the United States, resulting in an economic burden exceeding US$40 billion. The growing demand for faster recovery and better surgical outcomes has led to increased interest in orthobiologics. However, the wide variability in ligament healing, surgical techniques, biological factors, and preparation methods makes it challenging to generalize research results. More studies are needed to fully understand the impact of current orthobiologics on ligament healing. Although current research in ligament repair and reconstruction enhanced with orthobiologics shows promise, it is still not fully evidence-based.

01 Aug 2025·Arthroscopy, sports medicine, and rehabilitation

Resizing and Reshaping Anterior Cruciate Ligament Stump Tissue Does Not Compromise Cell Viability, and Infiltration Into Patellar Tendon Grafts Does Not Compromise Tensile Properties

Article

Author: Basso, Murilo ; Callanan, Mark ; Cohen, Achraf ; Heimur, Juliana ; Anz, Adam W ; Carssow, Nick ; Truett, Jessi

Purpose:

To determine whether a technique to process anterior cruciate ligament (ACL) stump tissue for needle infiltration into tendon grafts for ACL reconstruction would affect the viability of the cells within the tissue or the tensile properties of infiltrated grafts.

Methods:

ACL stump and Hoffa fat pad tissue was harvested from 13 ACL reconstruction patients and processed. Harvesting involved a standard arthroscopic shaver and an inline suction device. Processing involved 3 steps, 2 syringes, and 3 syringe transfer devices of decreasing size. After processing, tissue could pass through a needle for infiltration into ACL reconstruction tendon grafts. Tissue analysis was performed at each serial step of the processing technique and included cell counts and viability testing. Tensile testing involved 15 matched-pair cadaveric knees, from which bone-patellar tendon-bone (BPTB) grafts, stump tissue, and fat pad tissue were harvested. Harvested and processed tissue was infiltrated into BPTB grafts, and tensile biomechanical testing was performed.

Results:

Unprocessed tissue showed average cell viability (ACV) of 72.8% during cell viability testing. After step 1 of the process, ACV was 66.4%; after step 2, ACV was 73.1%; and after step 3, ACV was 67.1%. There was no significant difference in cell viability between processing steps (P = .528). When un-infiltrated control grafts were compared with infiltrated grafts, expected significant differences were found for weight (6.55 ± 1.51 g vs 8.91 ± 0.98 g, P < .001), width (9.53 ± 1.35 mm vs 13.74 ± 2.04 mm, P < .001), thickness (5.2 ± 1.26 mm vs 10.78 ± 2.11 mm, P < .001), and Young's modulus (94.55 ± 47.19 MPa vs 28.57 ± 16.37 MPa, P < .001). There were no significant differences in tensile failure load (536.65 ± 168.00 N vs 509.55 ± 139.31 N, P = .49), deformation at failure (9.34 ± 2.96 mm vs 9.28 ± 3.21 mm, P = .91), or stiffness (97.04 ± 32.34 N/mm vs 86.82 ± 24.37 N/mm, P = .11) between the groups.

Conclusions:

A technique to process remnant ACL and fat pad tissue for infiltration does not affect the viability of cells within the tissue. Infiltration of tissue into BPTB graft increases overall volume and mass and does not significantly alter the graft's tensile load to failure when compared with matched controls.

Clinical Relevance:

Evaluation of the biomechanical properties of a graft injected with minimally manipulated biologic material obtained at the time of harvest may provide laboratory data on the procedure's safety and viability as a direct delivery method for ACL grafts. These data could contribute to future studies involving clinical application during ACL reconstruction.

News (Medical) associated with Andrews Research & Education Foundation, Inc.

07 Nov 2024

·www.prnewswire.com

Renowned Retinal Surgeon and Medical Entrepreneur, Sunil Gupta, MD, Joins Nanoscope Board of Directors

DALLAS, Nov. 7, 2024 /PRNewswire/ -- Nanoscope Therapeutics Inc., a late-stage clinical biotechnology company developing gene therapies for inherited retinal diseases and age-related macular degenerations (AMD), today announced that Sunil Gupta, MD, has joined the Company's Board of Directors. Dr. Gupta is a nationally recognized retinal surgeon and a successful entrepreneur who brings deep experience in all phases of drug development and medical devices, including commercialization and manufacturing. "Dr. Gupta possesses an extraordinary combination of medical and entrepreneurial expertise around the treatment of inherited retinal diseases and dry age-related macular degeneration. He is a renowned, patient-focused physician, as well as an effective leader in executing clinical trials and operations. Dr. Gupta has truly advanced care for retina patients across the world. He will be an invaluable member of Nanoscope's board as we advance towards commercialization of our mutation-agnostic therapies to restore vision in millions of people blinded by retinal diseases and dry-AMD," said Sulagna Bhattacharya, Co-Founder and Chief Executive Officer of Nanoscope. "Nanoscope continues to advance work on its groundbreaking gene therapies for inherited retinal diseases such as retinitis pigmentosa (RP) and Stargardt, offering hope to patients for whom no cure currently exists," said Dr. Gupta. "The company's recent announcements highlighting the efficacy and safety results from its randomized Phase 2b trial in RP with subsequent BLA submission are revolutionary. With a Phase 3 registrational trial for Stargardt and a BLA filing in RP on the horizon, Nanoscope is closer to helping address serious unmet needs. Nanoscope has assembled a world-class team of scientists, physicians and business leaders, and I am excited to contribute." "I want to extend a warm welcome to Dr. Gupta and look forward to working with him. He joins us at a pivotal moment in Nanoscope's journey," said Glenn Sblendorio, Chairman of the Board. "With an enhanced regulatory pathway, we look forward to utilizing his strategic expertise as well as his network with the retinal community." Dr. Gupta is founder and clinical principal investigator at Retina Specialty Institute (RSI), one of the largest retinal research organizations in the United States serving patients in clinics across the south. He was also the founder and chief medical officer of USRetina—one of the largest associations of retina physicians in the United States specializing in drug distribution, GPO, and clinical operational processes and software development prior to its recent exit to McKesson. He founded and serves as chairman and chief medical officer of Intelligent Retinal Imaging Systems (IRIS), an FDA-cleared, cloud based, telemedicine platform for assessment of retinal eye disease in the primary care setting. Dr. Gupta's IRIS team is working to end preventable blindness due to diabetic retinopathy and other conditions around the world. Dr. Gupta was the past chairman of the Andrews Institute Sports Medicine Center and served on the board of the Andrews Research & Education Institute. In these efforts and beyond, he bridges industry and clinical care delivery organizations to optimize patient experience and outcomes. Dr. Gupta earned his medical degree from the University of Cincinnati College of Medicine and completed his residency in Ophthalmology at the Cullen Eye Institute at Baylor College of Medicine in Houston, Texas. He completed a Fellowship in Vitreoretinal Diseases & Surgery at the University of Iowa. About Nanoscope Therapeutics Inc. Nanoscope Therapeutics is developing gene-agnostic, sight-restoring optogenetic therapies for the millions of patients blinded by retinal degenerative diseases, for which no cure exists. The company's lead asset, MCO-010, recently reported topline results from the RESTORE Phase 2b multicenter, randomized, double-masked, sham-controlled clinical trial in the U.S. for retinitis pigmentosa (NCT04945772). The company has completed the Phase 2 STARLIGHT trial of MCO-010 therapy in Stargardt patients (NCT05417126) and recently announced plans to initiate a Phase 3 registrational trial in Q1 2025. MCO-010 has received FDA Fast Track designations and FDA orphan drug designations for both retinitis pigmentosa and Stargardt. Preclinical assets include non-viral laser-delivered MCO-020 gene therapy for geographic atrophy. Investor Contact: Argot Partners (212) 600-1902 [email protected] SOURCE Nanoscope Therapeutics WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Phase 2Fast TrackOrphan DrugExecutive ChangeClinical Result

100 Deals associated with Andrews Research & Education Foundation, Inc.

100 Translational Medicine associated with Andrews Research & Education Foundation, Inc.

Corporation Tree

Boost your research with our corporation tree data.

view full example data

Pipeline

Pipeline Snapshot as of 09 Dec 2025

No data posted

Deal

Boost your decision using our deal data.

view full example data

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Profit

Explore the financial positions of over 360K organizations with Synapse.

view full example data

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.

view full example data

Investment

Gain insights on the latest company investments from start-ups to established corporations.

view full example data

Financing

Unearth financing trends to validate and advance investment opportunities.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Andrews Research & Education Foundation, Inc.

Overview

Related

Corporation Tree

Pipeline

Pipeline Snapshot as of 09 Dec 2025

Deal

Translational Medicine

Profit

Grant & Funding(NIH)

Investment

Financing